In Silicon Valley, a secretive project is underway, spearheaded by Sam Altman and Oliver Mulherin from OpenAI. The couple is investing heavily in a startup aiming to develop technology that could potentially enable parents to have genetically edited babies, devoid of hereditary genetic disorders. Though this concept is groundbreaking, the notion of creating genetically engineered babies is widely contentious and deemed illegal and unethical in numerous regions globally. Despite these concerns, the affluent individuals are supporting this initiative, sparking unease within the scientific community.
According to a report by the Wall Street Journal, Sam Altman, Oliver Mulherin, and Brian Armstrong, the co-founder and CEO of Coinbase, are among the influential figures in Silicon Valley backing Preventive, a biotech startup. Preventive’s mission is to advance technology that could empower scientists to modify the genetic makeup of embryos, aiming to prevent the inheritance of severe genetic disorders in future generations.
Advocates of this technology view it as a revolutionary breakthrough capable of breaking the cycle of diseases that have plagued families for generations. However, critics argue that despite the noble intentions, the company is delving into scientifically risky, ethically murky, and potentially socially divisive territory.
To grasp the controversy surrounding this technology, it is essential to comprehend what genetically engineered babies entail. Essentially, before birth, babies inherit their parents’ DNA, carrying genetic diseases that are often incurable with current medical capabilities. Gene-editing seeks to manipulate the DNA of embryos, eliminating faulty sections using tools like CRISPR, potentially paving the way for disease-free generations.
Nevertheless, the practicality of gene-editing is intricate. Altering embryos involves making permanent hereditary changes that could impact future generations, with even minor errors potentially having unforeseen consequences. Critics also raise concerns about widening social disparities, where only the affluent can afford to engineer healthier offspring, potentially leading to societal divisions based on biology. Furthermore, there are apprehensions about the emergence of “designer babies,” where parents select traits like intelligence or appearance, a scenario many experts believe could be challenging to reverse once initiated.
Given the ethical and safety dilemmas, many researchers view this technology as both promising and perilous. Following the birth of gene-edited babies in China in 2018, global regulators have tightened restrictions on embryo editing for pregnancy, emphasizing the technology’s lack of readiness for practical application due to potential unknown side effects and long-term repercussions.
The startup Preventive contends that responsible advancement in this technology is achievable, advocating for early intervention to prevent inherited diseases across generations. Despite criticisms, Silicon Valley tycoons continue to invest in this idea, emphasizing disease prevention over human enhancement.
While Preventive asserts its current focus is solely disease prevention, not trait enhancement, proponents argue that stringent regulations and transparent oversight can anchor the technology in medical necessity. Nonetheless, even supporters of embryo editing acknowledge the moral complexity of this field, emphasizing the necessity of a clear ethical roadmap to navigate this intricate terrain effectively.